IGI Logo

Venus Remedies is currently trading at Rs. 327.55, up by 2.10 points or 0.65% from its previous closing of Rs. 325.45 on the BSE.

The scrip opened at Rs. 322.95 and has touched a high and low of Rs. 331.30 and Rs. 322.45 respectively. So far 1218 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 155.00 on 20-Mar-2023.

Last one week high and low of the scrip stood at Rs. 331.30 and Rs. 280.00 respectively. The current market cap of the company is Rs. 435.03 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.59% and 56.65% respectively.

Venus Remedies has expanded the reach of its oncology drugs in the Asia Commonwealth of Independent States (CIS) region with marketing authorisations from Ukraine for three cancer drugs -- paclitaxel, oxaliplatin and irinotecan. Its total volume of exports to Ukraine stands at $2.20 million. By strengthening its product portfolio in Ukraine, the company aims to increase this figure by 20 per cent in the next one year. The company is awaiting approval from Ukraine on another 10 applications for marketing authorisations.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.